Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma
Adding-on nivolumab was associated with improved OS in patients with advanced PDAC who achieved disease control following chemotherapy.
Authors
- Yu‐Wen Tien (ORCID: https://orcid.org/0000-0002-9126-2705)
- Ann‐Lii Cheng (ORCID: https://orcid.org/0000-0002-9152-6512)
- Yan‐Shen Shan (ORCID: https://orcid.org/0000-0002-2457-5189)
- Sung‐Hsin Kuo (ORCID: https://orcid.org/0000-0003-0054-887X)
- Bang‐Bin Chen (ORCID: https://orcid.org/0000-0001-7058-1427)
- Sz-Chi Chiu
- Kun‐Huei Yeh (ORCID: https://orcid.org/0000-0002-7306-174X)
- Jen‐Chieh Lee (ORCID: https://orcid.org/0000-0001-7739-5934)
- Shih‐Hung Yang
Institutions
- National Taiwan University (TW)
- National Taiwan University Hospital (TW)
- National Cheng Kung University Hospital (TW)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1007/s00262-024-03821-3
- Citations
- 5
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- National Taiwan University Hospital